Renal tubular dysgenesis of genetic origin

Summary

Renal tubular dysgenesis of genetic origin (MONDO:0009970) is a disease caused by variants in ACE, AGT, AGTR1, and 1 other genes, with 6 cohort genes. The dominant Reactome pathway is Metabolism of Angiotensinogen to Angiotensins (3 cohort genes).

At a glance

• Causal genes: ACE (GenCC Strong), AGT (GenCC Strong), AGTR1 (GenCC Strong), REN (GenCC Strong)
• Cohort genes: 6
• ClinVar variants: 544

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	renal tubular dysgenesis of genetic origin
Mondo ID	MONDO:0009970
OMIM	267430
Orphanet	97369
ICD-11	616055520
UMLS	C5681536
MedGen	1826125
GARD	0016854
Is cancer (heuristic)	no

Also known as: genetic renal tubular dysgenesis · renal tubular dysgenesis · renal tubular dysgenesis of genetic origin · RTD

Data availability: 544 ClinVar variants · 16 GenCC gene-disease records.

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › kidney disorder › renal tubular dysgenesis › renal tubular dysgenesis of genetic origin

Related subtypes (2): renal tubular dysgenesis due to twin-twin transfusion, drug-related renal tubular dysgenesis

Subtypes (1): renal tubular dysgenesis - ACE

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

544 retrieved; paginated sample, class counts are floors:

395 uncertain significance, 48 conflicting classifications of pathogenicity, 34 likely pathogenic, 24 benign/likely benign, 18 likely benign, 12 pathogenic/likely pathogenic, 10 pathogenic, 2 benign, 1 uncertain significance/vus-low

ClinVar	Variant (HGVS)	Gene	Classification	Review
1215324	NM_000789.4(ACE):c.2T>C (p.Met1Thr)	ACE	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
18063	NM_000789.4(ACE):c.798C>G (p.Tyr266Ter)	ACE	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
235336	NM_000789.4(ACE):c.1522C>T (p.Arg508Ter)	ACE	Pathogenic	criteria provided, multiple submitters, no conflicts
2506013	NM_000789.4(ACE):c.3409C>T (p.Gln1137Ter)	ACE	Pathogenic	criteria provided, single submitter
2573840	NM_000789.4(ACE):c.793C>T (p.Arg265Ter)	ACE	Pathogenic	criteria provided, multiple submitters, no conflicts
2712424	NM_000789.4(ACE):c.444_445insTTAGC (p.Arg149fs)	ACE	Pathogenic	criteria provided, multiple submitters, no conflicts
3001305	NM_000789.4(ACE):c.1186C>T (p.Gln396Ter)	ACE	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
3341107	NM_000789.4(ACE):c.21_30del (p.Arg8fs)	ACE	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
4531674	NM_000789.4(ACE):c.207G>A (p.Trp69Ter)	ACE	Pathogenic	criteria provided, single submitter
50209	NM_000789.4(ACE):c.2371C>T (p.Arg791Ter)	ACE	Pathogenic	criteria provided, multiple submitters, no conflicts
827586	NM_000789.4(ACE):c.1473_1475delinsA (p.Asp491fs)	ACE	Pathogenic	criteria provided, multiple submitters, no conflicts
871758	NM_000789.4(ACE):c.35TGC[1] (p.Leu13_Leu14del)	ACE	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
429714	NM_001384479.1(AGT):c.1060C>T	AGT	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
429788	NM_001384479.1(AGT):c.829+1G>T	AGT	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1685512	NM_000685.5(AGTR1):c.233del (p.Leu78fs)	AGTR1	Pathogenic	criteria provided, single submitter
2430252	NM_000685.5(AGTR1):c.415C>T (p.Arg139Ter)	AGTR1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
50206	NM_000685.5(AGTR1):c.251G>A (p.Trp84Ter)	AGTR1	Pathogenic	criteria provided, single submitter
13125	NM_000537.4(REN):c.36GCT[3] (p.Leu16del)	LOC107548112	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1940593	NM_000789.4(ACE):c.232G>T (p.Glu78Ter)	LOC130061383	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1067090	NM_000537.4(REN):c.249+1G>A	REN	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
13123	NM_000537.4(REN):c.145C>T (p.Arg49Ter)	REN	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
50210	NM_000537.4(REN):c.127C>T (p.Arg43Ter)	REN	Pathogenic	criteria provided, single submitter
1723253	NM_000789.4(ACE):c.1511del (p.Pro504fs)	ACE	Likely pathogenic	criteria provided, multiple submitters, no conflicts
1930250	NM_000789.4(ACE):c.945+2T>G	ACE	Likely pathogenic	criteria provided, multiple submitters, no conflicts
2585611	NM_000789.4(ACE):c.3G>T (p.Met1Ile)	ACE	Likely pathogenic	criteria provided, single submitter
2627964	NM_000789.4(ACE):c.973del (p.Val325fs)	ACE	Likely pathogenic	criteria provided, single submitter
3234989	NM_000789.4(ACE):c.1342+1G>T	ACE	Likely pathogenic	criteria provided, multiple submitters, no conflicts
3237477	NM_000789.4(ACE):c.798C>A (p.Tyr266Ter)	ACE	Likely pathogenic	criteria provided, single submitter
3391254	NM_000789.4(ACE):c.2062C>T (p.Gln688Ter)	ACE	Likely pathogenic	criteria provided, single submitter
3582403	NM_000789.4(ACE):c.2T>A (p.Met1Lys)	ACE	Likely pathogenic	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 39 · Orphanet: 6 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
ACE	Strong	Autosomal recessive	renal tubular dysgenesis of genetic origin	6
AGT	Strong	Autosomal recessive	renal tubular dysgenesis of genetic origin	3
AGTR1	Strong	Autosomal recessive	renal tubular dysgenesis of genetic origin	5
AGXT	Strong	Autosomal recessive	renal tubular dysgenesis of genetic origin	9
KCTD11	Strong	Autosomal recessive	renal tubular dysgenesis of genetic origin	8
REN	Strong	Autosomal recessive	renal tubular dysgenesis of genetic origin	8

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
ACE	Orphanet:97369	Renal tubular dysgenesis of genetic origin
AGT	Orphanet:97369	Renal tubular dysgenesis of genetic origin
AGTR1	Orphanet:97369	Renal tubular dysgenesis of genetic origin
AGXT	Orphanet:93598	Primary hyperoxaluria type 1
REN	Orphanet:217330	REN-related autosomal dominant tubulointerstitial kidney disease
REN	Orphanet:97369	Renal tubular dysgenesis of genetic origin

Cohort genes → proteins

6 cohort genes, 6 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	6

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
KCTD11	HGNC:21302	ENSG00000213859	Q693B1	BTB/POZ domain-containing protein KCTD11	gencc,clinvar
ACE	HGNC:2707	ENSG00000159640	P12821	Angiotensin-converting enzyme	gencc,clinvar
AGT	HGNC:333	ENSG00000135744	P01019	Angiotensinogen	gencc,clinvar
AGTR1	HGNC:336	ENSG00000144891	P30556	Type-1 angiotensin II receptor	gencc,clinvar
AGXT	HGNC:341	ENSG00000172482	P21549	Alanine–glyoxylate aminotransferase	gencc,clinvar
REN	HGNC:9958	ENSG00000143839	P00797	Renin	gencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
KCTD11	BTB/POZ domain-containing protein KCTD11	Plays a role as a marker and a regulator of neuronal differentiation; Up-regulated by a variety of neurogenic signals, such as retinoic acid, epidermal growth factor/EGF and NGFB/nerve growth factor.
ACE	Angiotensin-converting enzyme	Dipeptidyl carboxypeptidase that removes dipeptides from the C-terminus of a variety of circulating hormones, such as angiotensin I, bradykinin or enkephalins, thereby playing a key role in the regulation of blood pressure, electrolyte hom…
AGT	Angiotensinogen	Essential component of the renin-angiotensin system (RAS), a potent regulator of blood pressure, body fluid and electrolyte homeostasis.
AGTR1	Type-1 angiotensin II receptor	Receptor for angiotensin II, a vasoconstricting peptide, which acts as a key regulator of blood pressure and sodium retention by the kidney.
AGXT	Alanine–glyoxylate aminotransferase	Peroxisomal aminotransferase that catalyzes the transamination of glyoxylate to glycine and contributes to the glyoxylate detoxification.
REN	Renin	Renin is a highly specific endopeptidase, whose only known function is to generate angiotensin I from angiotensinogen in the plasma, initiating a cascade of reactions that produce an elevation of blood pressure and increased sodium retenti…

Protein-family classification

Druggable: 4 · Difficult: 0 · Unknown: 2 · Druggable fraction: 0.67

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Protease	2	12.2×	0.042
GPCR	1	4.0×	0.452
Enzyme (other)	1	2.0×	0.543
Other/Unknown	2	0.6×	0.936

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
KCTD11	Other/Unknown	no		T1-type_BTB, SKP1/BTB/POZ_sf, KCTD11/21_C
ACE	Protease	yes	3.4.15.1	Peptidase_M2
AGT	Other/Unknown	no		Serpin_fam, Angiotensinogen, Serpin_CS
AGTR1	GPCR	yes		ATII_AT1_rcpt, ATII_rcpt, GPCR_Rhodpsn
AGXT	Enzyme (other)	yes	2.6.1.44	Aminotrans_V_dom, PyrdxlP-dep_Trfase_major, PyrdxlP-dep_Trfase_small
REN	Protease	yes	3.4.23.15	Aspartic_peptidase_A1, Aspartic_peptidase_AS, Aspartic_peptidase_N

Expression context

Cohort genes with no expression data: 0.

6 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	6
unknown	0

Top tissues across cohort

Tissue	Cohort genes
liver	2
right lobe of liver	2
esophagus mucosa	1
lower esophagus mucosa	1
tibial nerve	1
ileal mucosa	1
left testis	1
right testis	1
lateral globus pallidus	1
placenta	1
skin of hip	1
subcutaneous adipose tissue	1
endometrium epithelium	1
adult mammalian kidney	1
decidua	1
stromal cell of endometrium	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
KCTD11	132	ubiquitous	marker	lower esophagus mucosa, tibial nerve, esophagus mucosa
ACE	177	ubiquitous	marker	ileal mucosa, right testis, left testis
AGT	255	broad	marker	right lobe of liver, liver, lateral globus pallidus
AGTR1	224		marker	skin of hip, placenta, subcutaneous adipose tissue
AGXT	125	tissue_specific	marker	right lobe of liver, liver, endometrium epithelium
REN	126	tissue_specific	marker	decidua, adult mammalian kidney, stromal cell of endometrium

Protein interactions among cohort

Intra-cohort edges: 6.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
AGT	5,091
ACE	3,659
REN	3,244
AGTR1	2,651
AGXT	2,648
KCTD11	420

Intra-cohort edges

A	B	Sources
ACE	AGT	biogrid_interaction, string_interaction
ACE	AGTR1	string_interaction
ACE	REN	string_interaction
AGT	AGTR1	intact, string_interaction
AGT	REN	biogrid_interaction, intact, string_interaction
AGTR1	REN	string_interaction

Structural data

PDB: 5 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
ACE	P12821	97
REN	P00797	91
AGT	P01019	22
AGXT	P21549	17
AGTR1	P30556	11

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
KCTD11	Q693B1	85.00

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 23. Enrichment computed across 6 evidence-associated genes (5 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Metabolism of Angiotensinogen to Angiotensins	3	380.7×	8e-07	ACE, AGT, REN
Peptide hormone metabolism	2	108.8×	0.002	ACE, AGT
Class A/1 (Rhodopsin-like receptors)	2	29.7×	0.010	AGT, AGTR1
Peptide ligand-binding receptors	2	29.7×	0.010	AGT, AGTR1
GPCR ligand binding	2	25.7×	0.011	AGT, AGTR1
G alpha (q) signalling events	2	22.9×	0.011	AGT, AGTR1
GPCR downstream signalling	2	17.4×	0.017	AGT, AGTR1
Glyoxylate metabolism and glycine degradation	1	152.3×	0.017	AGXT
Signaling by GPCR	2	16.0×	0.017	AGT, AGTR1
Protein localization	1	38.1×	0.060	AGXT
Peroxisomal protein import	1	34.6×	0.060	AGXT
Regulation of lipid metabolism by PPARalpha	1	28.2×	0.067	AGT
Cargo recognition for clathrin-mediated endocytosis	1	20.9×	0.082	AGTR1
PPARA activates gene expression	1	18.9×	0.082	AGT
Clathrin-mediated endocytosis	1	17.0×	0.082	AGTR1
Metabolism of proteins	2	5.0×	0.082	ACE, AGT
Metabolism	2	4.7×	0.084	AGT, AGXT
Metabolism of amino acids and derivatives	1	13.5×	0.092	AGXT
Signal Transduction	2	4.1×	0.096	AGT, AGTR1
G alpha (i) signalling events	1	7.8×	0.140	AGT
Membrane Trafficking	1	7.4×	0.140	AGTR1
Vesicle-mediated transport	1	7.0×	0.142	AGTR1
Metabolism of lipids	1	6.3×	0.149	AGT

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 6 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
renin-angiotensin regulation of aldosterone production	3	2808.7×	3e-09	AGT, AGTR1, REN
angiotensin-activated signaling pathway	3	766.0×	2e-07	ACE, AGT, AGTR1
regulation of vasoconstriction	3	401.2×	1e-06	ACE, AGT, AGTR1
kidney development	4	93.6×	1e-06	ACE, AGT, AGTR1, REN
regulation of renal output by angiotensin	2	2808.7×	2e-06	ACE, AGT
maintenance of blood vessel diameter homeostasis by renin-angiotensin	2	1872.4×	6e-06	AGT, AGTR1
regulation of renal sodium excretion	2	1404.3×	1e-05	AGT, AGTR1
regulation of systemic arterial blood pressure by renin-angiotensin	2	1123.5×	1e-05	ACE, AGTR1
regulation of blood pressure	3	110.9×	2e-05	ACE, AGT, REN
positive regulation of cholesterol metabolic process	2	702.2×	3e-05	AGT, AGTR1
amyloid-beta metabolic process	2	510.7×	6e-05	ACE, REN
angiotensin maturation	2	432.1×	7e-05	ACE, REN
low-density lipoprotein particle remodeling	2	351.1×	1e-04	AGT, AGTR1
positive regulation of macrophage derived foam cell differentiation	2	280.9×	2e-04	AGT, AGTR1
blood vessel diameter maintenance	2	208.1×	3e-04	ACE, AGTR1
positive regulation of reactive oxygen species metabolic process	2	170.2×	4e-04	AGT, AGTR1
blood vessel remodeling	2	127.7×	6e-04	ACE, AGT
regulation of cell growth	2	73.9×	0.002	AGT, AGTR1
regulation of blood volume by renin-angiotensin	1	2808.7×	0.002	AGT
mononuclear cell proliferation	1	2808.7×	0.002	ACE
G protein-coupled receptor signaling pathway coupled to cGMP nucleotide second messenger	1	1404.3×	0.003	AGT
regulation of angiotensin metabolic process	1	1404.3×	0.003	ACE
response to cGMP	1	1404.3×	0.003	REN
cell proliferation in bone marrow	1	1404.3×	0.003	ACE
negative regulation of gap junction assembly	1	1404.3×	0.003	ACE
male gonad development	2	52.0×	0.003	ACE, REN
positive regulation of inflammatory response	2	48.4×	0.003	AGT, AGTR1
phospholipase C-activating G protein-coupled receptor signaling pathway	2	43.9×	0.003	AGT, AGTR1
substance P catabolic process	1	936.2×	0.003	ACE
obsolete glycine biosynthetic process, by transamination of glyoxylate	1	936.2×	0.003	AGXT

Therapeutics

Drug target analysis

Approved (phase 4): 3 · Phase ≥3: 3 · Phased (≥1): 3 · Undrugged: 3

Druggability breadth: 6 of 6 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
ACE	TELMISARTAN
AGTR1	IRBESARTAN
REN	CAPTOPRIL

Top cohort targets by molecule count

Symbol	Molecules	Max phase
AGTR1	88	4
ACE	31	4
REN	13	4
KCTD11	0	0
AGT	0	0
AGXT	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
TELMISARTAN	4	ACE, AGTR1
MOEXIPRIL	4	ACE
RAMIPRIL	4	ACE
LISINOPRIL ANHYDROUS	4	ACE
SITAGLIPTIN	4	ACE
TRANDOLAPRIL	4	ACE
CAPTOPRIL	4	ACE, REN
PERINDOPRIL	4	ACE
QUINAPRIL	4	ACE
LOSARTAN	4	ACE, AGTR1
FOSINOPRIL	4	ACE
IMIDAPRIL	4	ACE
ENALAPRILAT ANHYDROUS	4	ACE
ENALAPRIL	4	ACE
BENAZEPRIL	4	ACE
IRBESARTAN	4	AGTR1
SARALASIN	4	AGTR1
LOSARTAN POTASSIUM	4	AGTR1
CANDESARTAN CILEXETIL	4	AGTR1
CLOTRIMAZOLE	4	AGTR1
SIMVASTATIN	4	AGTR1
VALSARTAN	4	AGTR1
RIMONABANT	4	AGTR1
ARIPIPRAZOLE	4	AGTR1
PONATINIB	4	AGTR1
OXYMETHOLONE	4	AGTR1
OLMESARTAN MEDOXOMIL	4	AGTR1
NORGESTIMATE	4	AGTR1
ROCURONIUM	4	AGTR1
PYRVINIUM	4	AGTR1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 3.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
REN	541	Binding:472, Functional:68, ADMET:1
AGTR1	421	Binding:315, Functional:105, ADMET:1
ACE	304	Binding:288, Functional:8, ADMET:5, Unclassified:3
AGXT	8	Binding:8
AGT	2	Binding:2
KCTD11	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
ACE	3.4.15.1	peptidyl-dipeptidase A
AGXT	2.6.1.44, 2.6.1.51	alanine-glyoxylate transaminase, serine-pyruvate transaminase
REN	3.4.23.15	renin

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
ACE	304
AGTR1	421
REN	541

Pharmacogenomics

Cohort genes with a PharmGKB record: 6; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
TELMISARTAN	4	ACE, AGTR1
MOEXIPRIL	4	ACE
RAMIPRIL	4	ACE
LISINOPRIL ANHYDROUS	4	ACE
SITAGLIPTIN	4	ACE
TRANDOLAPRIL	4	ACE
CAPTOPRIL	4	ACE, REN
PERINDOPRIL	4	ACE
QUINAPRIL	4	ACE
LOSARTAN	4	ACE, AGTR1
FOSINOPRIL	4	ACE
IMIDAPRIL	4	ACE
ENALAPRILAT ANHYDROUS	4	ACE
ENALAPRIL	4	ACE
BENAZEPRIL	4	ACE
IRBESARTAN	4	AGTR1
SARALASIN	4	AGTR1
LOSARTAN POTASSIUM	4	AGTR1
CANDESARTAN CILEXETIL	4	AGTR1
CLOTRIMAZOLE	4	AGTR1
SIMVASTATIN	4	AGTR1
VALSARTAN	4	AGTR1
RIMONABANT	4	AGTR1
ARIPIPRAZOLE	4	AGTR1
PONATINIB	4	AGTR1
OXYMETHOLONE	4	AGTR1
OLMESARTAN MEDOXOMIL	4	AGTR1
NORGESTIMATE	4	AGTR1
ROCURONIUM	4	AGTR1
PYRVINIUM	4	AGTR1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	3	ACE, AGTR1, REN
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	1	AGXT
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	2	KCTD11, AGT

Undrugged target profiles

3 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
AGT	2	AGTR1, ACE, REN
KCTD11	1	—
AGXT	8	—

Clinical trials & evidence

Clinical trials

Clinical trials: 0.